AIK-C measles vaccine expressing fusion protein of respiratory syncytial virus induces protective antibodies in cotton rats

Vaccine

Volumn 29, Issue 7, 2011, Pages 1481-1490

  Sawada, Akihito ^a   Komase, Katsuhiro ^b   Nakayama, Tetsuo ^a  

^a KITASATO UNIVERSITY   (Japan)

^b NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

Author keywords

Cotton rat; Measles virus (MV); Neutralizing antibodies; Respiratory syncytial virus (RSV)

Indexed keywords

AIK C MEASLES VACCINE; CROSS REACTING ANTIBODY; HYBRID PROTEIN; NEUTRALIZING ANTIBODY; PROTEIN RSV F; PROTEIN RSV G; RECOMBINANT VACCINE; RESPIRATORY SYNCYTIAL VIRUS VACCINE; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY TITER; ANTIGEN EXPRESSION; ARTICLE; CELL INFILTRATION; COTTON RAT; GENE DOSAGE; HISTOPATHOLOGY; IMMUNOGENICITY; INTERSTITIAL PNEUMONIA; MONONUCLEAR CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; TEMPERATURE SENSITIVITY; VIRUS GENOME;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CELL LINE; CROSS REACTIONS; HUMANS; LUNG; MEASLES VACCINE; NEUTRALIZATION TESTS; PNEUMONIA, VIRAL; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; RESPIRATORY SYNCYTIAL VIRUSES; RNA, VIRAL; SIGMODONTINAE; VACCINES, SYNTHETIC; VIRAL FUSION PROTEINS;

EID: 79151480243     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.12.028     Document Type: Article

References (46)

1. Lamb R.A., Parks G.D. Paramyxoviridae: the viruses and their replication. Fields virology 2007, 1449-1496. Lippincott Williams & Wilkins, Philadelphia. 5th ed. D.M. Knipe, P.M. Howley (Eds.).
2. Collins P.L., Hill M.G., Camargo E., Grosfeld H., Chanock R.M., Murphy B.R. Production of infectious human respiratory syncytial virus from cloned cDNA confirms an essential role for the transcription elongation factor from the 5' proximal open reading frame of the M2 mRNA in gene expression and provides a capability for vaccine development. Proc Natl Acad Sci USA 1995, 92(25):11563-11567.
3. Chanock R., Finberg L. Recovery from infants with respiratory illness of a virus related to chimpanzee coryza agent (CCA). II. Epidemiologic aspects of infection in infants and young children. Am J Hyg 1957, 66(3):291-300.
4. Anderson L.J., Hierholzer J.C., Tsou C., Hendry R.M., Fernie B.F., Stone Y., et al. Antigenic characterization of respiratory syncytial virus strains with monoclonal antibodies. J Infect Dis 1985, 151(4):626-633.
5. La Via W.V., Grant S.W., Stutman H.R., Marks M.I. Clinical profile of pediatric patients hospitalized with respiratory syncytial virus infection. Clin Pediatr (Phila) 1993, 32(8):450-454.
6. Henderson F.W., Collier A.M., Clyde W.A., Denny F.W. Respiratory-syncytial-virus infections, reinfections and immunity. A prospective, longitudinal study in young children. N Engl J Med 1979, 300(10):530-534.
7. Ebbert J.O., Limper A.H. Respiratory syncytial virus pneumonitis in immunocompromised adults: clinical features and outcome. Respiration 2005, 72(3):263-269.
8. Anderson L.J., Parker R.A., Strikas R.L. Association between respiratory syncytial virus outbreaks and lower respiratory tract deaths of infants and young children. J Infect Dis 1990, 161(4):640-646.
9. González P.A., Bueno S.M., Riedel C.A., Kalergis A.M. Impairment of T cell immunity by the respiratory syncytial virus: targeting virulence mechanisms for therapy and prophylaxis. Curr Med Chem 2009, 16(34):4609-4625.
10. Becker Y. Respiratory syncytial virus (RSV) evades the human adaptive immune system by skewing the Th1/Th2 cytokine balance toward increased levels of Th2 cytokines and IgE, markers of allergy-a review. Virus Genes 2006, 33(2):235-252.
11. Fisher R.G., Crowe J.E., Johnson T.R., Tang Y.W., Graham B.S. Passive IgA monoclonal antibody is no more effective than IgG at protecting mice from mucosal challenge with respiratory syncytial virus. J Infect Dis 1999, 180(4):1324-1327.
12. Piedra P.A., Cron S.G., Jewell A., Hamblett N., McBride R., Palacio M.A., et al. Immunogenicity of a new purified fusion protein vaccine to respiratory syncytial virus: a multi-center trial in children with cystic fibrosis. Vaccine 2003, 21(19-20):2448-2460.
13. Lofland J.H., O'Connor J.P., Chatterton M.L., Moxey E.D., Paddock L.E., Nash D.B., et al. Palivizumab for respiratory syncytial virus prophylaxis in high-risk infants: a cost-effectiveness analysis. Clin Ther 2000, 22(11):1357-1369.
14. Murphy B.R., Prince G.A., Walsh E.E., Kim H.W., Parrott R.H., Hemming V.G., et al. Dissociation between serum neutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine. J Clin Microbiol 1986, 24(2):197-202.
15. Murphy B.R., Walsh E.E. Formalin-inactivated respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion-inhibiting activity. J Clin Microbiol 1988, 26(8):1595-1597.
16. Wright P.F., Belshe R.B., Kim H.W., Van Voris L.P., Chanock R.M. Administration of a highly attenuated, live respiratory syncytial virus vaccine to adults and children. Infect Immun 1982, 37(1):397-400.
17. Whitehead S.S., Firestone C.Y., Karron R.A., Crowe J.E., Elkins W.R., Collins P.L., et al. Addition of a missense mutation present in the L gene of respiratory syncytial virus (RSV) cpts530/1030 to RSV vaccine candidate cpts248/404 increases its attenuation and temperature sensitivity. J Virol 1999, 73(2):871-877.
18. Collins P.L., Purcell R.H., London W.T., Lawrence L.A., Chanock R.M., Murphy B.R. Evaluation in chimpanzees of vaccinia virus recombinants that express the surface glycoproteins of human respiratory syncytial virus. Vaccine 1990, 8:164-168.
19. Nakayama T., Komase K., Uzuka R., Hoshi A., Okafuji T. Leucine at position 278 of the AIK-C measles virus vaccine strain fusion protein is responsible for reduced syncytium formation. J Gen Virol 2001, 82:2143-2150.
20. Ballart I., Eschle D., Cattaneo R., Schmid A., Metzler M., Chan J., et al. Infectious measles virus from cloned cDNA. EMBO J 1990, 9(2):379-384.
21. Komase K., Nakayama T., Iijima M., Miki K., Kawanishi R., Uejima H. The phosphoprotein of attenuated measles AIK-C vaccine strain contributes to its temperature-sensitive phenotype. Vaccine 2006, 24(6):826-834.
22. Tang R.S., MacPhail M., Schickli J.H., Kaur J., Robinson C.L., Lawlor H.A., et al. Parainfluenza virus type 3 expressing the native or soluble fusion (F) protein of respiratory syncytial virus (RSV) confers protection from RSV infection in African green monkeys. J Virol 2004, 78(20):11198-11207.
23. Zhan X., Hurwitz J.L., Krishnamurthy S., Takimoto T., Boyd K., Scroggs R.A., et al. Respiratory syncytial virus (RSV) fusion protein expressed by recombinant Sendai virus elicits B-cell and T-cell responses in cotton rats and confers protection against RSV subtypes A and B. Vaccine 2007, 25(52):8782-8793.
24. Rima B.K., Earle J.A., Yeo R.P., Herlihy L., Baczko K., ter Meulen V., et al. Temporal and geographical distribution of measles virus genotypes. J Gen Virol 1995, 76(Pt 5):1173-1180.
25. Makino S., Sasaki K., Nakamura N., Nakagawa M., Nakajima S. Studies on the modification of the live AIK measles vaccine. II. Development and evaluation of the live AIK-C measles vaccine. Kitasato Arch Exp Med 1974, 47(1-2):13-21.
26. Bolotovski V.M., Grabowsky M., Clements C.J., Albrecht P., Brenner E.R., Zargaryantzs A.I., et al. Immunization of 6 and 9 month old infants with AIK-C, Edmonston-Zagreb, Leningrad-16 and Schwarz strains of measles vaccine. Int J Epidemiol 1994, 23(5):1069-1077.
27. Pabst H.F., Spady D.W., Carson M.M., Krezolek M.P., Barreto L., Wittes R.C. Cell-mediated and antibody immune responses to AIK-C and Connaught monovalent measles vaccine given to 6 month old infants. Vaccine 1999, 17(15-16):1910-1918.
28. Cutts F.T., Grabowsky M., Markowitz L.E. The effect of dose and strain of live attenuated measles vaccines on serological responses in young infants. Biologicals 1995, 23(1):95-106.
29. Nakayama T., Onoda K. Vaccine adverse events reported in post-marketing study of the Kitasato Institute from 1994 to 2004. Vaccine 2007, 25(3):570-576.
30. Kobune F., Sakata H., Sugiura A. Marmoset lymphoblastoid cells as a sensitive host for isolation of measles virus. J Virol 1990, 64(February (2)):700-705.
31. Kumada A., Komase K., Nakayama T. Recombinant measles AIK-C strain expressing current wild-type hemagglutinin protein. Vaccine 2004, 22(3-4):309-316.
32. Sutter G., Ohlmann M., Erfle V. Non-replicating vaccinia vector efficiently expresses bacteriophage T7 RNA polymerase. FEBS Lett 1995, 371(1):9-12.
33. Kapikian A.Z., Mitchell R.H., Chanock R.M., Shvedoff R.A., Stewart C.E. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol 1969, 89(4):405-421.
34. Polack F.P., Teng M.N., Collins P.L., Prince G.A., Exner M., Regele H., et al. A role for immune complexes in enhanced respiratory syncytial virus disease. J Exp Med 2002, 196(6):859-865.
35. Karron R.A., Wright P.F., Crowe J.E., Clements-Mann M.L., Thompson J., Makhene M., et al. Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccines in chimpanzees and in human adults, infants, and children. J Infect Dis 1997, 176(6):1428-1436.
36. Teng M.N., Whitehead S.S., Bermingham A., St Claire M., Elkins W.R., Murphy B.R., et al. Recombinant respiratory syncytial virus that does not express the NS1 or M2-2 protein is highly attenuated and immunogenic in chimpanzees. J Virol 2000, 74(19):9317-9321.
37. Wyatt L.S., Whitehead S.S., Venanzi K.A., Murphy B.R., Moss B. Priming and boosting immunity to respiratory syncytial virus by recombinant replication-defective vaccinia virus MVA. Vaccine 1999, 18(5-6):392-397.
38. de Wall L., Wyatt L.S., Yuksel S., Van Amerongen G., Moss B., Niester H.G., et al. Vaccination of infant macaques with a recombinant modified vaccinia virus Ankara expressing the respiratory syncytial virus F and G genes does not predispose for immunopathology. Vaccine 2004, 22:923-926.
39. Jones B., Zhan X., Mishin V., Slobod K.S., Surman S., Russell C.J., et al. Human PIV-2 recombinant Sendai virus (rSeV) elicits durable immunity and combines with two additional rSeVs to protect against hPIV-1, hPIV-2, hPIV-3, and RSV. Vaccine 2009, 27(12):1848-1857.
40. Desprès P., Combredet C., Frenkiel M.P., Lorin C., Brahic M., Tangy F. Live measles vaccine expressing the secreted form of the West Nile virus envelope glycoprotein protects against West Nile virus encephalitis. J Infect Dis 2005, 191(2):207-214.
41. Wild T.F., Buckland R. Functional aspects of envelope-associated measles virus proteins. Curr Top Microbiol Immunol 1995, 191:51-64.
42. Haga T., Murayama N., Shimizu Y., Saito A., Sakamoto T., Morita T., et al. Analysis of antibody response by temperature-sensitive measles vaccine strain in the cotton rat model. Comp Immunol Microbiol Infect Dis 2009, 32(5):395-406.
43. Liniger M., Zuniga A., Tamin A., Azzouz-Morin T.N., Knuchel M., Marty R.R., et al. Induction of neutralising antibodies and cellular immune responses against SARS coronavirus by recombinant measles viruses. Vaccine 2008, 26(17):2164-2174.
44. del Valle J.R., Devaux P., Hodge G., Wegner N.J., McChesney M.B., Cattaneo R. A vectored measles virus induces hepatitis B surface antigen antibodies while protecting macaques against measles virus challenge. J Virol 2007, 81(19):10597-10605.
45. Liniger M., Zuniga A., Morin T.N., Combardiere B., Marty R., Wiegand M., et al. Recombinant measles viruses expressing single or multiple antigens of human immunodeficiency virus (HIV-1) induce cellular and humoral immune responses. Vaccine 2009, 27(25-26):3299-3305.
46. Boukhvalova M.S., Prince G.A., Blanco F.C.G. The cotton rat model of respiratory viral infections pathogenesis and immunity. Biologicals 2009, 37:152-159.